The present invention relates to a method for isolating Glu-Plasminogen from a solution containing Glu-Plasminogen and one or more other polypeptides, wherein the method comprises the step of eluting the Glu-Plasminogen from the cation exchange solid phase with an elution buffer of a pH in the range of 6.2 to 6.5. Furthermore, the present invention relates to a composition comprising Glu-Plasminogen obtainable from the method of the invention.
A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
2.
FETUIN-A FOR TREATING OR PREVENTING PATHOLOGICAL INFLAMMATIONS
The present invention relates to Fetuin-A for use in a method for treating or preventing a pathological inflammation in a patient, wherein the patient is preferably characterized by having a blood serum level of Fetuin-A below a non-pathological blood serum level, and/or a blood serum level of tumor necrosis factor alpha (TNF-α) above the average blood serum level found in the healthy population.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a method for isolating Fetuin-A, comprising a step of contacting the fluid containing Fetuin-A to a solid phase that bears moieties of an anthraquinone compound, in particular Reactive Blue 2. Furthermore, the present invention refers a composition comprising Fetuin-A obtainable from such method and uses thereof. Moreover, the invention refers to a method for determining the activity of Fetuin-A.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
B01D 15/08 - Selective adsorption, e.g. chromatography
C07D 311/62 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
B01D 15/16 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
4.
PROCESS FOR ISOLATING PLASMINOGEN FROM A BLOOD PLASMA FRACTION
The present invention relates to a method for isolating plasminogen from a blood plasma fraction comprising dispersing a precipitate of a blood plasma fraction containing plasminogen in a basic aqueous buffer, separating solid parts thereof and removing at least parts of other proteins, and extracting the plasminogen with an acidic aqueous buffer.
The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.
The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.
The present invention relates to a method for isolating plasminogen from a blood plasma fraction comprising dispersing a precipitate of a blood plasma fraction containing plasminogen in a basic aqueous buffer, separating solid parts thereof and removing at least parts of other proteins, and extracting the plasminogen with an acidic aqueous buffer.
The present invention relates to plasminogen for use in a method for preventing or treating a thrombotic event in a patient, wherein the patient is at risk of developing or is suffering from microthrombi.
The invention provides a method for preparing Fetuin A from a Fetuin A containing source material, especially from a biological liquid. The method comprises the steps of providing a Fetuin A containing source material, loading the Fetuin A containing source material on a hydrophobic interaction chromatography material, wherein Fetuin A adsorbs to the chromatography material, and eluting Fetuin A.
C07K 1/20 - Partition-, reverse-phase or hydrophobic interaction chromatography
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 38/57 - Protease inhibitors from animalsProtease inhibitors from humans
10.
PLASMINOGEN FOR USE IN TREATING AND PREVENTING LUNG DYSFUNCTION
The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.
The present invention relates to a method for preparing iron-depleted ferritin, in particular apoferritin, wherein said method comprises the provision of an iron ion-adsorbing zeolite separated from a ferritin-containing fluid by a semipermeable layer. Furthermore, the present invention refers to iron-depleted ferritin, in particular apoferritin, for use in a method of treating an acute or chronic inflammation and treating and preventing a neurodegenerative disease.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
12.
EPITOPES OF CLOSTRIDIUM DIFFICILE TOXINS A AND B AND USES THEREOF
The present invention relates to a polypeptide comprising an epitope having a sequence homology of at least 75% to a sequence section of both Clostridium difficile toxin A and B. Moreover, the present invention refers to a vaccine comprising such polypeptide. The invention further relates to an antibody binding to Clostridium difficile toxins A and B and to a method for isolating and/or detecting such antibody and to uses of the polypeptides and antibodies.
The present invention relates to plasminogen for use in a method for preventing or treating a thrombotic event in a patient, wherein the patient is at risk of developing or is suffering from microthrombi.
The present invention relates to plasminogen for use in a method for preventing or treating a thrombotic event in a patient, wherein the patient is at risk of developing or is suffering from microthrombi.
Surprisingly, it was found that zeolites can be used to decrease the concentration of inorganic ions, such as calcium ions, from a body fluid, such as plasma, in sufficient way. Such decrease of the concentration of inorganic ions, such as calcium ions, was found to lead to an inhibition of hemostasis including an inhibition of coagulation, especially inhibiting the activation of factor VII and the formation of fibrin.
The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.
The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.
The present invention relates to a method for isolating Glu-plasminogen, said method comprising the anion exchange chromatography of blood plasma or a plasma fraction comprising Glu-plasminogen. Furthermore, the present invention relates to Glu-plasminogen obtainable from the method of the present invention and its use in a method for treating a patient suffering from or being at risk of developing a disorder selected from the group consisting of organ failure, a thrombotic event, arterial obstructive disease, microcirculation, disseminated intravascular coagulation (DIC), and a combination of two or more thereof.
patents
